Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Like other weight loss drugs, Zepbound is an injection patients give themselves once a week. In the news release, Lilly recommends that the drug be used in combination with a reduced-calorie diet ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Zepbound is expected to be available in the United States by the end of the year in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) at a list price of $1,059.87, which is approximately 20% ...